These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 35172216)

  • 1. Expectations and acceptability of long-acting injectable antiretrovirals by patients living with HIV/AIDS.
    Palacios C; Wilpotte C; Adda A; Allaf S; Thibaut P; Chas J; Siguier M; Pialoux G
    Infect Dis Now; 2022 Jun; 52(4):238-239. PubMed ID: 35172216
    [No Abstract]   [Full Text] [Related]  

  • 2. Determinants of heterosexual men's demand for long-acting injectable pre-exposure prophylaxis (PrEP) for HIV in urban South Africa.
    Cheng CY; Quaife M; Eakle R; Cabrera Escobar MA; Vickerman P; Terris-Prestholt F
    BMC Public Health; 2019 Jul; 19(1):996. PubMed ID: 31340785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-Acting Injectable Antiretroviral Treatment Acceptability and Preferences: A Qualitative Study Among US Providers, Adults Living with HIV, and Parents of Youth Living with HIV.
    Simoni JM; Beima-Sofie K; Mohamed ZH; Christodoulou J; Tapia K; Graham SM; Ho R; Collier AC
    AIDS Patient Care STDS; 2019 Mar; 33(3):104-111. PubMed ID: 30844308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiretrovirals for HIV prevention: when should they be recommended?
    Kiselinova M; De Spiegelaere W; Verhofstede C; Callens SF; Vandekerckhove L
    Expert Rev Anti Infect Ther; 2014 Apr; 12(4):431-45. PubMed ID: 24621251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. News from CROI 2022 - caveats using antiretrovirals as HIV prophylaxis.
    Barreiro P; Soriano V
    AIDS Rev; 2022 Apr; 24(2):98-99. PubMed ID: 35544744
    [No Abstract]   [Full Text] [Related]  

  • 6. Long-Acting Injectable ART and PrEP Among Women in Six Cities Across the United States: A Qualitative Analysis of Who Would Benefit the Most.
    Philbin MM; Bergen S; Parish C; Kerrigan D; Kinnard EN; Reed S; Cohen MH; Sosanya O; Sheth AN; Adimora AA; Cocohoba J; Goparaju L; Golub ET; Vaughn M; Gutierrez JI; Fischl MA; Alcaide M; Metsch LR
    AIDS Behav; 2022 Apr; 26(4):1260-1269. PubMed ID: 34648131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Awareness about and willingness to use long-acting injectable pre-exposure prophylaxis (LAI-PrEP) among people who use drugs.
    Shrestha R; DiDomizio EE; Kim RS; Altice FL; Wickersham JA; Copenhaver MM
    J Subst Abuse Treat; 2020 Oct; 117():108058. PubMed ID: 32811633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interest in Long-Acting Injectable Pre-exposure Prophylaxis (LAI PrEP) Among Women in the Women's Interagency HIV Study (WIHS): A Qualitative Study Across Six Cities in the United States.
    Philbin MM; Parish C; Kinnard EN; Reed SE; Kerrigan D; Alcaide ML; Cohen MH; Sosanya O; Sheth AN; Adimora AA; Cocohoba J; Goparaju L; Golub ET; Fischl M; Metsch LR
    AIDS Behav; 2021 Mar; 25(3):667-678. PubMed ID: 32910351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV pre-exposure prophylaxis (PrEP).
    Tumarkin E; Siedner MJ; Bogoch II
    BMJ; 2019 Jan; 364():k4681. PubMed ID: 30655299
    [No Abstract]   [Full Text] [Related]  

  • 10. Designing PrEP and early HIV treatment interventions for implementation among female sex workers in South Africa: developing and learning from a formative research process.
    Eakle R; Mutanha N; Mbogua J; Sibanyoni M; Bourne A; Gomez G; Venter F; Rees H
    BMJ Open; 2018 Jun; 8(6):e019292. PubMed ID: 29903784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High interest in a long-acting injectable formulation of pre-exposure prophylaxis for HIV in young men who have sex with men in NYC: a P18 cohort substudy.
    Meyers K; Rodriguez K; Moeller RW; Gratch I; Markowitz M; Halkitis PN
    PLoS One; 2014; 9(12):e114700. PubMed ID: 25502768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidemiological impact and cost-effectiveness of providing long-acting pre-exposure prophylaxis to injectable contraceptive users for HIV prevention in South Africa: a modelling study.
    van Vliet MM; Hendrickson C; Nichols BE; Boucher CA; Peters RP; van de Vijver DA
    J Int AIDS Soc; 2019 Dec; 22(12):e25427. PubMed ID: 31855323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An evaluation of cabotegravir for HIV treatment and prevention.
    Canetti D; Spagnuolo V
    Expert Opin Pharmacother; 2021 Mar; 22(4):403-414. PubMed ID: 33112699
    [No Abstract]   [Full Text] [Related]  

  • 14. Long-Acting Injectable Antiretrovirals in Incarcerated Populations - Challenges and Opportunities.
    Akiyama MJ; Spaulding AC; Nijhawan AE
    N Engl J Med; 2022 Nov; 387(19):1728-1730. PubMed ID: 36342112
    [No Abstract]   [Full Text] [Related]  

  • 15. Acceptability and feasibility of short message service to improve ART medication adherence among people living with HIV/AIDS receiving antiretroviral treatment at Adama hospital medical college, Central Ethiopia.
    Endebu T; Deksisa A; Dugasa W; Mulu E; Bogale T
    BMC Public Health; 2019 Oct; 19(1):1315. PubMed ID: 31638936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acceptability of a long-acting injectable HIV prevention product among US and African women: findings from a phase 2 clinical Trial (HPTN 076).
    Tolley EE; Li S; Zangeneh SZ; Atujuna M; Musara P; Justman J; Pathak S; Bekker LG; Swaminathan S; Stanton J; Farrior J; Sista N
    J Int AIDS Soc; 2019 Oct; 22(10):e25408. PubMed ID: 31651098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of long-acting injectable antiretroviral agents for human immunodeficiency Virus: A review.
    Ariyo OE; Jones CE
    J Clin Virol; 2022 Jan; 146():105032. PubMed ID: 34883407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Injectable Antiretroviral Drugs: Back to the Future.
    Berruti M; Riccardi N; Canetti D; Lo Caputo S; Taramasso L; Di Biagio A
    Viruses; 2021 Feb; 13(2):. PubMed ID: 33540877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acceptability of and Preferences for Long-Acting Injectable HIV PrEP and Other PrEP Modalities among Sexual Minority Men in Nigeria, Africa.
    Ogunbajo A; Tsai AC; Kanki PJ; Mayer KH
    AIDS Behav; 2022 Jul; 26(7):2363-2375. PubMed ID: 35061117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interest in Long-Acting Injectable PrEP in a Cohort of Men Who have Sex with Men in China.
    Meyers K; Wu Y; Qian H; Sandfort T; Huang X; Xu J; Zhang J; Xia W; Glidden D; Wu H; Shang H
    AIDS Behav; 2018 Apr; 22(4):1217-1227. PubMed ID: 28707025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.